News

How do estrogen, testosterone, and aromatase shape binge eating and bulimia risk? Let's explore brain biomarkers and future hormone-aware treatments.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

AFSP and JED plan a 2026 merger to form the largest US suicide prevention nonprofit, uniting research, youth mental health programs, advocacy, and community support.

Learn how antipsychotics and stress raise prolactin, what symptoms to spot, and when to test—plus practical options to lower levels.

Psychedelic therapies surge, but a rushed FDA shortcut risks safety; learn why ibogaine claims need rigorous trials and oversight.

Two-dose oral R‑MDMA, EMP-01, cuts social anxiety symptoms and real‑world avoidance in phase 2a study, with strong responder rates and good tolerability.

Evidence links some hormonal contraceptives—especially in teens—to higher depression risk; see which types matter and how to monitor mood.

Chatbot makers face rising lawsuits over suicide, addiction, and psychosis.

Authoritarian governments are detrimental to mental health. Let's explore a historic case.

Vibrance-1 phase 2 results show alixorexton improves narcolepsy type 1 severity, cognition, and fatigue for 13 weeks with good tolerability.

Data suggest PBFT02 therapy boosts progranulin and slows neurodegeneration markers in early FTD.

ASAM’s new youth SUD criteria help clinicians deliver developmentally tailored, prevention-first care with coordinated family and community supports.

Learn more about how sex hormones and prolactin shape brain circuits, revealing new biomarkers and treatment strategies for eating disorders, psychosis, and depression.

Psychiatry probes why public apologies may manipulate or hinder forgiveness, and what humility and remorse reveal in conflicts from courts to clinics.

New evidence shows lithium adds minimal weight in bipolar disorder and explains why some gain occurs—plus practical tips to prevent it.

Learn how therapists navigate honesty, boundaries, and transference when creative patients bring novels, paintings, or provocative images into psychotherapy.

Artemis astronauts spotlight psychiatric medication, mental health support, and trust—revealing why psychiatry’s village mindset strengthens care, leadership, and ethics.

High-potency cannabis surges; psychiatry confronts psychosis risk, dependence, and data gaps—why clinicians must guide safer use now.

Faster aging may be linked to schizophrenia, according to new research.

How creativity and wisdom can grow after 80, from Matisse to modern psychiatry—boosting purpose, brain health, and connection in later life.

"While studying the CAT scan, I picture Groucho Marx..."

Bupropion may cause dose-linked tinnitus; this case shows symptoms improve after dose reduction, helping manage depression without stopping treatment.

Shared pathophysiology between Alzheimer disease and autism may expand diagnosis and treatment opportunities.

A new US-based grant program seeks to create training content for health care providers who want to be able to deliver investigational COMP360 psilocybin treatment.

Explore how sigma‑1 receptors shape ER–mitochondria signaling, calm neuroinflammation, and inspire therapies from fluvoxamine to dextromethorphan.

Psychiatry training must catch up with chatbot literacy, intake, safety, ethics, and supervised AI integration.

With Artemis II’s journey in mind, a psychiatrist urges mental health action on climate denial, resilience, and saving Earth before it’s too late.

A pharma expert and clinician shares perspectives on developing treatments.